NASD · Healthcare · Drug Manufacturers - Specialty & Generic · USA
Organogenesis Holdings Inc is a micro cap company (market value under $300 million) in the Drug Manufacturers - Specialty & Generic industry.
Organogenesis develops, manufactures, and sells regenerative medicine products for treating wounds and soft tissue injuries. The company offers skin substitutes, amniotic membrane products, and placental allografts to hospitals, wound care centers, surgery centers, and physician offices. Its portfolio addresses chronic and acute wounds, as well as tendon and ligament damage.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Organogenesis Holdings Inc stock.
Undervalued: intrinsic value $2.72 per share, market price $0.81, margin of safety 70.3% (as of 2026-11-17).
Discounting its cash flows at 7.4% values the shares at $2.72; the price of $0.81 is 70% below that value.
17 more funds hold it; the full list is part of the paid plan.
All 82 Drug Manufacturers - Specialty & Generic stocks
ORGO is undervalued (as of the 2026-11-17 close). Discounting its cash flows at 7.4% values the shares at $2.72; the price of $0.81 is 70% below that value.
$2.72 per share (as of the 2026-11-17 close), against a market price of $0.81. That is a margin of safety of 70.3%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.